Vectura Share Discussion Threads

[polaris] 11/1/2021 13:38

No trading statement today - last year was a Monday in early January. Maybe next week?

VEC will also present at JPM Healthcare conference on Thursday. Might have some general information on the CDMO transition.

[diesel] 10/1/2021 21:19

Base...you’re right...
Surely they were a CDMO company before, but also developing some candidates outright.
With everything I here it seems more style over substance, I know in this sector timescales are often protracted, but we are overdue something substantive from this new team, the recent news has come from actions started years ago....

[base7] 10/1/2021 17:39

Interesting that they say they have transitioned to aCDMO company,rather than transitioning .I would consider us to have transitioned when our turnover from that source is ,at least 10s of millions,if not more,relative to our other income streams & the positive take from this perspective is that is clearly in the plan.

[volvo] 10/1/2021 17:28

Only doing this if the market is following

[volvo] 10/1/2021 11:38

....it’s a really exciting time to join us. We have recently transitioned to being a CDMO business, which means you’ll have exposure to working with interesting customers and technology from across the inhaled therapy space.

The work you do will span our entire range of medical devices, those already on the market and those at earlier development stages, providing regulatory support for clinical trials, right through to commercialisation and release.

This is a new role to Vectura, so you will have the opportunity to make your mark and leave a legacy. You will also lead a small team and drive them successfully through the next few years of growth and change....

[volvo] 08/1/2021 17:13

....you sure, recon big week coming up

[a1ord53] 08/1/2021 17:09

Volvo, there is nothing behind this auction trade.
There are trackers of FTSE 250 and algo trading settlement.
That’s it.

[volvo] 08/1/2021 16:36

Another massive auction buy, roll on next week and the TS.

[fhmktg] 08/1/2021 12:22

$6.25 million in 2020 and low single digit % on net sales

[dodkins] 08/1/2021 12:15

QVM149 was approved in July for the EU although I haven't seen anything mentioned since. Does this qualify as another new revenue stream?

[alexchry] 08/1/2021 12:03

Diesel, I agree completely with your last sentence, I think the expression all fur coat and no knickers sums up the board and company at the moment.

[diesel] 08/1/2021 12:00

Best, I’ve been in since SKP days, buying and selling over the years, at the moment my biggest holding but am beginning to unwind at the 130 level. With all known info I think we can see a trading range between 125-140, with a support level of 130 when the GSK money is in the bank. Not impressed with the new management, new positions, flashy titles, new bonus package, glitzy but less informative website and a couple of contracts that on close inspection are somewhat questionable.

[volvo] 08/1/2021 10:20

Hikma will give a trading statement on 25th Feb and an update re early indication of Advair sales.

[best1467] 07/1/2021 20:53

Some interesting and as usual very well researched and informative posts noticed Pacira results today and as already mentioned the 32 million looking good for YE 2021.
All the present value drivers are from the past management and SKP in particular so we certainly need to see some progress with the CDMO strategy but I’m more excited about the Elipta generic platform which hopefully with the GSK patent issue out of the way will now start to progress.
But when you look back over the last few years which have been disappointing to say the least to actually get two lots of positive news recently and see the stock price approaching £1.30 it’s a pleasant change for sure and well deserved for the long term holders on this thread

[justiceforthemany] 07/1/2021 17:37

GSK payment due late January so yes should be hearing final details and confirmation of sum in the coming days.
Results wise these are usually in March.

A note on Hikma - has tripled since its low in 2018 - market got things very wrong!

[volvo] 07/1/2021 16:39

Big take in the auction again over 50pc of todays turnover, recon Monday is the day for the TS....should make for interesting reading.

[volvo] 07/1/2021 15:06

As with all things.....the facts will come out eventually, but I like to get on a moving bus.

[diesel] 07/1/2021 14:38

Polaris, thanks for the info, as always well researched.

[volvo] 07/1/2021 14:32

polaris Hikma are one the largest Generic prescription medication supplier in the entire US.

They already have massive supply chains and manufacturing supplying into chain stores, wholesalers, distributors, health systems and government agencies. They have all the contacts.

I will just reiterate in a non 'rampy' way your going to be v surprised just how much market share of Advair they are aiming at.

[polaris] 07/1/2021 13:40

Another player in the US generic Advair market would certainly impact any market share for GSK, Mylan and Hikma/VEC. The market listed in the link is in the 12 month period to March 2020. That was during the period where the price cutting was in play. I'd expect the overall market value to be significantly less than that now.

I should also note that while there are only 3 players, GSK are actually there twice. They also launched an authorised generic in 2019 to go alongside their original product, under distribution agreement to Prasco LLC. see:



That might explain why they still have £500 M or so in annual Advair US sales. They manufacture an internal generic, distributed by an outside supplier, as well as the original product.

[polaris] 07/1/2021 13:22

hmmm. Turns out there is another potential player in the market. See the following:



From submission date in Mid May and the slightly extended period for replies due to Covid situation, i'd expect some news in Q1 2021. This would be a 4th product to market and one that has slipped somewhat under the radar.

[base7] 07/1/2021 13:07

I agree with your key point A153,although I will be interested to hear what Will says about our CDMO before condemning him & his 2 senior colleagues.Hopefully they will be rising to the challenge, using their ( presumably ) extensive network & the substantial resources available to Vec to demonstrate that our new direction has the potential to create a substantial business, in addition to our existing legacy business & several income streams.The trading update, hopefully next week,should give some clues, even if scant on detail

[redips2] 07/1/2021 12:37

Stuck a5k toe in.... see how it goes.